Search

Displaying results 4911 - 4920 of 10000 in total
  1. Drug

    Ifenprodil

    go.drugbank.com/drugs/DB08954
    ApprovedInvestigationalWithdrawn

    [A196128] Ifenprodil is being investigated for its potential utility in treating COVID-19 in an ongoing phase 2b/3 clinical trial (NCT04382924).[L16343] … N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.

  2. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline … GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK.

  3. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15507
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  4. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16726
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  5. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  6. Drug

    Grapiprant

    go.drugbank.com/drugs/DB12836
    InvestigationalVet approved

    [A39838] This type of molecules is currently in development for veterinary patients.[A39816] This class of drugs was defined in 2013 by the World Health Organization. … [L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836]

  7. Drug

    Pilaralisib

    go.drugbank.com/drugs/DB11772
    Investigational

    Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). … Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.

  8. Drug

    Aluminum zirconium pentachlorohydrate

    go.drugbank.com/drugs/DB11147
    Approved

    Aluminum zirconium pentachlorohydrate is a common active ingredient in personal care products as an antiperspirant agent. … Its main mechanism of action is through blocking the pores via formation of polymer complex and preventing sweat from leaving the body.

    Products: On Duty 24 Hours Clear Protection Roll-On Anti-Perspirant Deodorant
  9. Drug

    Heptaminol

    go.drugbank.com/drugs/DB13574
    Investigational

    Categories: Vasodilators Used in Cardiac Diseases
  10. Drug

    Dalfopristin

    go.drugbank.com/drugs/DB01764
    Approved

    Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.